Progyny Key Executives
This section highlights Progyny's key executives, including their titles and compensation details.
Find Contacts at Progyny
(Showing 0 of )
Progyny Earnings
This section highlights Progyny's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | $0.37 | $0.42 |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $0.37 | $0.40 |
| Read Transcript | Q2 | 2024 | 2024-08-06 | $0.36 | $0.43 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $0.14 | $0.39 |
| Read Transcript | Q4 | 2023 | 2024-02-27 | $0.11 | $0.32 |
| Read Transcript | Q3 | 2023 | 2023-11-07 | $0.12 | $0.16 |
| Read Transcript | Q2 | 2023 | 2023-08-03 | $0.10 | $0.15 |
| Read Transcript | Q1 | 2023 | 2023-05-08 | $0.07 | $0.18 |
Financial Statements
Access annual & quarterly financial statements for Progyny, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.17B | $1.09B | $786.91M | $500.62M | $344.86M |
| Cost of Revenue | $913.86M | $849.80M | $619.59M | $388.49M | $274.80M |
| Gross Profit | $253.36M | $238.80M | $167.32M | $112.14M | $70.06M |
| Gross Profit Ratio | 21.71% | 21.94% | 21.26% | 22.40% | 20.32% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $121.96M | $117.13M | $98.33M | $59.62M | $46.70M |
| Selling and Marketing Expenses | $63.95M | $59.49M | $45.66M | $20.18M | $15.01M |
| Selling General and Administrative Expenses | $185.91M | $176.62M | $143.98M | $79.80M | $61.71M |
| Other Expenses | $- | $- | $286.00K | $-366.00K | $210.00K |
| Operating Expenses | $185.91M | $176.62M | $143.98M | $79.80M | $61.71M |
| Cost and Expenses | $1.10B | $1.03B | $763.57M | $468.28M | $336.51M |
| Interest Income | $15.75M | $- | $814.00K | $461.00K | $121.00K |
| Interest Expense | $- | $- | $814.00K | $461.00K | $121.00K |
| Depreciation and Amortization | $- | $2.28M | $1.60M | $1.30M | $1.91M |
| EBITDA | $67.45M | $64.47M | $24.94M | $33.64M | $10.25M |
| EBITDA Ratio | 5.78% | 5.92% | 3.17% | 6.72% | 2.97% |
| Operating Income | $67.45M | $62.18M | $23.34M | $32.34M | $8.35M |
| Operating Income Ratio | 5.78% | 5.71% | 2.97% | 6.46% | 2.42% |
| Total Other Income Expenses Net | $15.75M | $8.51M | $1.10M | $95.00K | $331.00K |
| Income Before Tax | $83.20M | $70.69M | $24.44M | $32.44M | $8.68M |
| Income Before Tax Ratio | 7.13% | 6.49% | 3.11% | 6.48% | 2.52% |
| Income Tax Expense | $28.87M | $8.65M | $-5.92M | $-33.33M | $-37.78M |
| Net Income | $54.34M | $62.04M | $30.36M | $65.77M | $46.46M |
| Net Income Ratio | 4.66% | 5.70% | 3.86% | 13.14% | 13.47% |
| EPS | $0.59 | $0.65 | $0.33 | $0.74 | $0.54 |
| EPS Diluted | $0.57 | $0.62 | $0.30 | $0.66 | $0.47 |
| Weighted Average Shares Outstanding | 91.48M | 95.02M | 92.20M | 89.11M | 85.72M |
| Weighted Average Shares Outstanding Diluted | 95.45M | 100.67M | 99.96M | 100.36M | 99.06M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $298.43M | $286.62M | $304.09M | $278.08M | $269.94M | $280.89M | $279.37M | $258.39M | $214.32M | $205.37M | $195.00M | $172.22M | $127.55M | $122.28M | $128.65M | $122.13M | $100.30M | $98.93M | $64.61M | $81.02M |
| Cost of Revenue | $235.00M | $227.38M | $235.81M | $215.67M | $213.05M | $218.27M | $218.73M | $199.75M | $169.83M | $159.38M | $151.12M | $139.27M | $102.44M | $93.79M | $99.03M | $93.23M | $79.64M | $78.09M | $52.65M | $64.42M |
| Gross Profit | $63.43M | $59.24M | $68.28M | $62.41M | $56.89M | $62.62M | $60.64M | $58.64M | $44.49M | $45.99M | $43.89M | $32.95M | $25.11M | $28.49M | $29.62M | $28.91M | $20.67M | $20.84M | $11.96M | $16.60M |
| Gross Profit Ratio | 21.26% | 20.67% | 22.45% | 22.44% | 21.08% | 22.29% | 21.71% | 22.69% | 20.76% | 22.40% | 22.51% | 19.13% | 19.69% | 23.30% | 23.02% | 23.67% | 20.60% | 21.06% | 18.50% | 20.49% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $32.03M | $30.33M | $31.17M | $28.43M | $28.18M | $29.52M | $30.07M | $29.35M | $28.21M | $23.57M | $23.55M | $22.99M | $17.61M | $14.99M | $13.94M | $13.09M | $14.73M | $12.12M | $10.17M | $9.48M |
| Selling and Marketing Expenses | $15.62M | $16.46M | $16.42M | $15.45M | $14.91M | $14.91M | $15.38M | $14.28M | $12.98M | $11.17M | $11.50M | $10.02M | $7.70M | $4.44M | $4.03M | $4.01M | $4.78M | $3.35M | $3.61M | $3.27M |
| Selling General and Administrative Expenses | $47.65M | $46.79M | $47.59M | $43.88M | $43.09M | $44.44M | $45.46M | $43.63M | $41.19M | $34.74M | $35.05M | $33.01M | $25.30M | $19.43M | $17.96M | $17.10M | $19.50M | $15.47M | $13.78M | $12.74M |
| Other Expenses | $- | $- | $- | $3.36M | $1.72M | $1.71M | $1.28M | $498.00K | $275.00K | $82.00K | $25.00K | $-96.00K | $-293.00K | $-92.00K | $12.00K | $7.00K | $32.00K | $11.00K | $3.00K | $164.00K |
| Operating Expenses | $47.65M | $46.79M | $47.59M | $43.88M | $43.09M | $44.44M | $45.46M | $43.63M | $41.19M | $34.74M | $35.05M | $33.01M | $25.30M | $19.43M | $17.96M | $17.10M | $19.50M | $15.47M | $13.78M | $12.74M |
| Cost and Expenses | $282.64M | $274.17M | $283.40M | $259.56M | $256.14M | $262.70M | $264.19M | $243.38M | $211.01M | $194.12M | $186.17M | $172.28M | $127.74M | $113.22M | $117.00M | $110.33M | $99.14M | $93.57M | $66.42M | $77.17M |
| Interest Income | $1.87M | $5.50M | $816.00K | $632.00K | $742.00K | $1.03M | $706.00K | $822.00K | $560.00K | $202.00K | $40.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $560.00K | $- | $40.00K | $12.00K | $83.00K | $144.00K | $252.00K | $18.00K | $17.00K | $17.00K | $5.00K | $150.00K |
| Depreciation and Amortization | $- | $- | $754.00K | $716.00K | $634.00K | $579.00K | $527.00K | $541.00K | $446.00K | $405.00K | $386.00K | $364.00K | $316.00K | $267.00K | $296.00K | $422.00K | $464.00K | $462.00K | $460.00K | $520.00K |
| EBITDA | $15.79M | $12.46M | $21.44M | $19.24M | $14.43M | $18.77M | $15.71M | $15.55M | $3.75M | $11.66M | $9.22M | $306.00K | $128.00K | $9.33M | $11.95M | $12.23M | $1.62M | $5.82M | $-612.00K | $4.38M |
| EBITDA Ratio | 5.29% | 4.35% | 7.05% | 6.92% | 5.35% | 6.68% | 5.62% | 6.02% | 1.75% | 5.68% | 4.73% | 0.18% | 0.10% | 7.63% | 9.29% | 10.01% | 1.62% | 5.89% | -0.95% | 5.40% |
| Operating Income | $15.79M | $12.46M | $20.69M | $18.52M | $13.80M | $18.19M | $15.18M | $15.01M | $3.31M | $11.26M | $8.84M | $-58.00K | $-188.00K | $9.06M | $11.66M | $11.81M | $1.16M | $5.36M | $-1.82M | $3.86M |
| Operating Income Ratio | 5.29% | 4.35% | 6.80% | 6.66% | 5.11% | 6.48% | 5.44% | 5.81% | 1.54% | 5.48% | 4.53% | -0.03% | -0.15% | 7.41% | 9.06% | 9.67% | 1.16% | 5.42% | -2.82% | 4.76% |
| Total Other Income Expenses Net | $1.87M | $5.50M | $4.38M | $3.99M | $2.46M | $2.74M | $1.98M | $1.32M | $835.00K | $284.00K | $65.00K | $-84.00K | $-210.00K | $52.00K | $264.00K | $-11.00K | $15.00K | $-6.00K | $8.00K | $314.00K |
| Income Before Tax | $17.66M | $17.96M | $25.07M | $22.52M | $16.26M | $20.93M | $17.17M | $16.33M | $4.14M | $11.54M | $8.90M | $-142.00K | $-398.00K | $9.12M | $11.92M | $11.80M | $1.18M | $5.36M | $-1.81M | $4.17M |
| Income Before Tax Ratio | 5.92% | 6.27% | 8.24% | 8.10% | 6.02% | 7.45% | 6.14% | 6.32% | 1.93% | 5.62% | 4.57% | -0.08% | -0.31% | 7.46% | 9.27% | 9.66% | 1.17% | 5.41% | -2.80% | 5.15% |
| Income Tax Expense | $7.13M | $7.54M | $8.58M | $5.62M | $2.79M | $5.03M | $2.18M | $-1.35M | $733.00K | $-1.67M | $135.00K | $-5.11M | $-15.48M | $-7.68M | $-6.81M | $-3.37M | $-37.90M | $17.00K | $-5.00K | $116.00K |
| Net Income | $10.53M | $10.42M | $16.48M | $16.90M | $13.47M | $15.90M | $14.99M | $17.68M | $3.41M | $13.21M | $8.77M | $4.97M | $15.08M | $16.80M | $18.73M | $15.17M | $39.07M | $5.36M | $-1.81M | $4.06M |
| Net Income Ratio | 3.53% | 3.64% | 5.42% | 6.08% | 4.99% | 5.66% | 5.37% | 6.84% | 1.59% | 6.43% | 4.50% | 2.89% | 11.82% | 13.74% | 14.56% | 12.42% | 38.95% | 5.41% | -2.80% | 5.01% |
| EPS | $0.12 | $0.12 | $0.18 | $0.18 | $0.14 | $0.17 | $0.16 | $0.19 | $0.04 | $0.14 | $0.09 | $0.05 | $0.17 | $0.19 | $0.21 | $0.17 | $0.45 | $0.06 | $-0.02 | $0.05 |
| EPS Diluted | $0.12 | $0.11 | $0.17 | $0.17 | $0.13 | $0.16 | $0.15 | $0.18 | $0.03 | $0.13 | $0.09 | $0.05 | $0.15 | $0.17 | $0.19 | $0.15 | $0.39 | $0.05 | $-0.02 | $0.04 |
| Weighted Average Shares Outstanding | 85.81M | 90.07M | 93.87M | 96.48M | 95.98M | 95.50M | 94.74M | 93.83M | 93.06M | 92.32M | 97.42M | 99.42M | 90.54M | 89.57M | 88.17M | 87.40M | 86.51M | 86.27M | 85.28M | 84.54M |
| Weighted Average Shares Outstanding Diluted | 88.91M | 93.82M | 97.84M | 101.05M | 100.75M | 100.88M | 100.62M | 100.17M | 100.06M | 99.82M | 99.67M | 99.94M | 100.32M | 100.37M | 99.81M | 100.11M | 99.02M | 98.97M | 85.28M | 99.67M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $162.31M | $97.30M | $120.08M | $91.41M | $70.31M |
| Short Term Investments | $65.64M | $273.79M | $69.22M | $28.00M | $38.99M |
| Cash and Short Term Investments | $227.95M | $371.09M | $189.30M | $119.42M | $109.30M |
| Net Receivables | $235.32M | $241.87M | $240.07M | $134.56M | $75.66M |
| Inventory | $- | $- | $- | $1 | $- |
| Other Current Assets | $9.44M | $27.45M | $4.49M | $9.13M | $10.52M |
| Total Current Assets | $472.72M | $640.41M | $433.86M | $258.54M | $190.22M |
| Property Plant Equipment Net | $29.63M | $27.82M | $15.27M | $12.83M | $12.07M |
| Goodwill | $15.53M | $11.88M | $11.88M | $11.88M | $11.88M |
| Intangible Assets | $1.30M | $- | $99.00K | $599.00K | $1.21M |
| Goodwill and Intangible Assets | $16.84M | $11.88M | $11.98M | $12.48M | $13.09M |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $84.93M | $73.12M | $77.89M | $71.27M | $37.97M |
| Other Non-Current Assets | $2.98M | $3.40M | $3.99M | $2.94M | $573.00K |
| Total Non-Current Assets | $134.38M | $116.21M | $109.13M | $99.53M | $63.70M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $607.10M | $756.62M | $542.99M | $358.06M | $253.93M |
| Account Payables | $95.10M | $125.43M | $109.29M | $61.40M | $43.51M |
| Short Term Debt | $2.86M | $2.15M | $1.23M | $1.23M | $1.23M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $34.02M | $-1.23M |
| Other Current Liabilities | $70.67M | $58.38M | $49.02M | $36.19M | $33.04M |
| Total Current Liabilities | $168.63M | $185.95M | $159.54M | $98.82M | $77.79M |
| Long Term Debt | $16.41M | $17.24M | $6.48M | $7.42M | $8.32M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $3.02M | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $876.00K |
| Total Non-Current Liabilities | $16.41M | $17.24M | $6.48M | $7.42M | $9.19M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $185.04M | $203.19M | $166.02M | $106.24M | $86.98M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K |
| Retained Earnings | $- | $89.97M | $27.93M | $-2.42M | $-68.19M |
| Accumulated Other Comprehensive Income Loss | $39.00K | $2.82M | $501.00K | $-93.00K | $1.00K |
| Other Total Stockholders Equity | $422.01M | $460.63M | $348.52M | $254.33M | $235.13M |
| Total Stockholders Equity | $422.06M | $553.43M | $376.97M | $251.82M | $166.95M |
| Total Equity | $422.06M | $553.43M | $376.97M | $251.82M | $166.95M |
| Total Liabilities and Stockholders Equity | $607.10M | $756.62M | $542.99M | $358.06M | $253.93M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $607.10M | $756.62M | $542.99M | $358.06M | $253.93M |
| Total Investments | $65.64M | $273.79M | $69.22M | $28.00M | $38.99M |
| Total Debt | $19.27M | $19.39M | $7.71M | $7.42M | $8.32M |
| Net Debt | $-143.04M | $-77.91M | $-112.36M | $-83.99M | $-61.99M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $162.31M | $91.48M | $94.96M | $114.96M | $97.30M | $158.07M | $170.57M | $155.32M | $120.08M | $72.52M | $54.73M | $38.82M | $91.41M | $92.22M | $48.75M | $29.82M | $70.31M | $53.97M | $49.39M | $91.63M |
| Short Term Investments | $65.64M | $144.24M | $167.23M | $256.87M | $273.79M | $177.48M | $111.92M | $52.57M | $69.22M | $68.47M | $67.66M | $66.86M | $28.00M | $22.09M | $45.22M | $77.09M | $38.99M | $50.99M | $41.98M | $- |
| Cash and Short Term Investments | $227.95M | $235.72M | $262.19M | $371.83M | $371.09M | $335.55M | $282.50M | $207.89M | $189.30M | $140.99M | $122.39M | $105.68M | $119.42M | $114.31M | $93.97M | $106.92M | $109.30M | $104.96M | $91.38M | $91.63M |
| Net Receivables | $235.32M | $280.72M | $293.80M | $297.21M | $241.87M | $268.77M | $264.96M | $313.25M | $240.07M | $258.04M | $229.86M | $198.12M | $134.56M | $135.18M | $140.77M | $116.67M | $75.66M | $78.30M | $65.00M | $65.86M |
| Inventory | $- | $- | $- | $1 | $1 | $- | $1 | $- | $- | $1 | $1 | $- | $1 | $1 | $- | $- | $- | $1 | $1 | $2 |
| Other Current Assets | $9.44M | $29.86M | $26.26M | $12.47M | $27.45M | $6.95M | $13.68M | $5.95M | $4.49M | $2.84M | $8.26M | $10.46M | $9.13M | $9.87M | $7.51M | $8.44M | $10.52M | $2.66M | $6.67M | $8.88M |
| Total Current Assets | $472.72M | $546.30M | $582.24M | $681.51M | $640.41M | $611.27M | $561.13M | $527.08M | $433.86M | $401.87M | $356.38M | $309.03M | $258.54M | $254.42M | $238.49M | $227.80M | $190.22M | $184.59M | $159.71M | $161.94M |
| Property Plant Equipment Net | $29.63M | $29.37M | $28.44M | $27.41M | $27.82M | $27.74M | $27.95M | $27.75M | $15.27M | $14.33M | $13.63M | $13.41M | $12.83M | $12.73M | $12.17M | $12.04M | $12.07M | $3.51M | $3.60M | $3.67M |
| Goodwill | $15.53M | $15.80M | $15.61M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M |
| Intangible Assets | $1.30M | $1.45M | $1.48M | $- | $- | $- | $- | $- | $99.00K | $223.00K | $348.00K | $473.00K | $599.00K | $723.00K | $848.00K | $973.00K | $1.21M | $1.48M | $1.75M | $2.02M |
| Goodwill and Intangible Assets | $16.84M | $17.24M | $17.09M | $11.88M | $11.88M | $11.88M | $11.88M | $11.88M | $11.98M | $12.10M | $12.23M | $12.35M | $12.48M | $12.60M | $12.73M | $12.85M | $13.09M | $13.36M | $13.63M | $13.90M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $84.93M | $63.76M | $67.88M | $70.27M | $73.12M | $72.03M | $77.06M | $79.24M | $77.89M | $78.02M | $76.34M | $76.43M | $71.27M | $55.83M | $48.15M | $41.34M | $37.97M | $- | $- | $- |
| Other Non-Current Assets | $2.98M | $3.30M | $2.98M | $3.23M | $3.40M | $3.59M | $3.51M | $3.77M | $3.99M | $4.13M | $4.29M | $4.31M | $2.94M | $1.10M | $536.00K | $556.00K | $573.00K | $592.00K | $611.00K | $629.00K |
| Total Non-Current Assets | $134.38M | $113.67M | $116.39M | $112.79M | $116.21M | $115.24M | $120.41M | $122.64M | $109.13M | $108.58M | $106.50M | $106.50M | $99.53M | $82.26M | $73.58M | $66.79M | $63.70M | $17.46M | $17.85M | $18.21M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $607.10M | $659.97M | $698.63M | $794.30M | $756.62M | $726.51M | $681.54M | $649.72M | $542.99M | $510.44M | $462.88M | $415.52M | $358.06M | $336.68M | $312.07M | $294.59M | $253.93M | $202.05M | $177.55M | $180.15M |
| Account Payables | $95.10M | $130.46M | $151.75M | $130.17M | $125.43M | $132.04M | $130.16M | $145.62M | $109.29M | $104.16M | $92.66M | $84.68M | $61.40M | $55.42M | $54.68M | $57.31M | $43.51M | $42.21M | $31.93M | $39.44M |
| Short Term Debt | $2.86M | $- | $- | $- | $2.15M | $- | $- | $- | $1.23M | $- | $- | $- | $1.23M | $- | $- | $- | $1.23M | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $1 | $57.19M | $-1.79M | $-1.45M | $-1.23M | $- | $- | $- | $- | $34.02M | $-1.23M | $-1.23M | $-1.23M | $- | $- | $- | $- |
| Other Current Liabilities | $70.67M | $78.01M | $73.63M | $75.75M | $58.38M | $61.38M | $63.74M | $61.24M | $49.02M | $52.70M | $52.24M | $44.04M | $36.19M | $49.06M | $44.11M | $43.69M | $33.04M | $31.96M | $25.73M | $19.62M |
| Total Current Liabilities | $168.63M | $208.47M | $225.38M | $205.92M | $185.95M | $193.42M | $193.90M | $206.87M | $159.54M | $156.87M | $144.90M | $128.72M | $98.82M | $104.48M | $98.78M | $101.00M | $77.79M | $74.17M | $57.67M | $59.06M |
| Long Term Debt | $16.41M | $16.62M | $17.06M | $16.78M | $17.24M | $17.70M | $18.14M | $18.46M | $6.48M | $6.72M | $6.96M | $7.19M | $7.42M | $7.65M | $7.87M | $8.10M | $8.32M | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $6.68M | $- | $- | $- | $3.02M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $438.00K | $876.00K | $876.00K | $876.00K | $617.00K | $327.00K | $- |
| Total Non-Current Liabilities | $16.41M | $16.62M | $17.06M | $16.78M | $17.24M | $17.70M | $18.14M | $18.46M | $6.48M | $6.72M | $6.96M | $7.19M | $7.42M | $8.09M | $8.75M | $8.97M | $9.19M | $617.00K | $327.00K | $- |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $185.04M | $225.10M | $242.44M | $222.70M | $203.19M | $211.12M | $212.04M | $225.32M | $166.02M | $163.59M | $151.85M | $135.91M | $106.24M | $112.57M | $107.53M | $109.97M | $86.98M | $74.78M | $57.99M | $59.06M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $8.00K |
| Retained Earnings | $- | $133.78M | $123.35M | $106.87M | $89.97M | $76.50M | $60.60M | $45.61M | $27.93M | $24.53M | $11.31M | $2.55M | $-2.42M | $-17.50M | $-34.30M | $-53.03M | $-68.19M | $-105.88M | $-111.24M | $-109.43M |
| Accumulated Other Comprehensive Income Loss | $39.00K | $330.00K | $2.02M | $2.75M | $2.82M | $1.85M | $1.08M | $724.00K | $501.00K | $205.00K | $18.00K | $-11.00K | $-93.00K | $-312.00K | $-270.00K | $-50.00K | $1.00K | $17.00K | $5.00K | $0 |
| Other Total Stockholders Equity | $422.01M | $300.76M | $330.81M | $461.98M | $460.63M | $437.04M | $407.81M | $378.06M | $348.52M | $322.12M | $299.68M | $277.07M | $254.33M | $241.92M | $239.10M | $237.69M | $235.13M | $233.12M | $230.78M | $230.51M |
| Total Stockholders Equity | $422.06M | $434.88M | $456.19M | $571.60M | $553.43M | $515.39M | $469.50M | $424.40M | $376.97M | $346.86M | $311.02M | $279.62M | $251.82M | $224.11M | $204.54M | $184.62M | $166.95M | $127.27M | $119.56M | $121.09M |
| Total Equity | $422.06M | $434.88M | $456.19M | $571.60M | $553.43M | $515.39M | $469.50M | $424.40M | $376.97M | $346.86M | $311.02M | $279.62M | $251.82M | $224.11M | $204.54M | $184.62M | $166.95M | $127.27M | $119.56M | $121.09M |
| Total Liabilities and Stockholders Equity | $607.10M | $659.97M | $698.63M | $794.30M | $756.62M | $726.51M | $681.54M | $649.72M | $542.99M | $510.44M | $462.88M | $415.52M | $358.06M | $336.68M | $312.07M | $294.59M | $253.93M | $202.05M | $177.55M | $180.15M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $607.10M | $659.97M | $698.63M | $794.30M | $756.62M | $726.51M | $681.54M | $649.72M | $542.99M | $510.44M | $462.88M | $415.52M | $358.06M | $336.68M | $312.07M | $294.59M | $253.93M | $202.05M | $177.55M | $180.15M |
| Total Investments | $65.64M | $144.24M | $167.23M | $256.87M | $273.79M | $177.48M | $111.92M | $52.57M | $69.22M | $68.47M | $67.66M | $66.86M | $28.00M | $22.09M | $45.22M | $77.09M | $38.99M | $50.99M | $41.98M | $- |
| Total Debt | $19.27M | $16.62M | $19.87M | $19.29M | $19.39M | $17.70M | $18.14M | $18.46M | $7.71M | $6.72M | $6.96M | $7.19M | $7.42M | $7.65M | $7.87M | $8.10M | $8.32M | $- | $- | $- |
| Net Debt | $-143.04M | $-74.86M | $-75.09M | $-95.67M | $-77.91M | $-140.38M | $-152.43M | $-136.86M | $-112.36M | $-65.80M | $-47.77M | $-31.63M | $-83.99M | $-84.58M | $-40.87M | $-21.72M | $-61.99M | $-53.97M | $-49.39M | $-91.63M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $54.34M | $62.04M | $30.36M | $65.77M | $46.46M |
| Depreciation and Amortization | $3.17M | $2.28M | $1.60M | $1.30M | $1.91M |
| Deferred Income Tax | $-10.46M | $3.75M | $-6.62M | $-33.30M | $-37.97M |
| Stock Based Compensation | $128.13M | $122.61M | $100.75M | $33.71M | $12.82M |
| Change in Working Capital | $- | $-17.42M | $-59.49M | $-51.26M | $7.35M |
| Accounts Receivables | $-9.87M | $-21.74M | $-119.30M | $-68.68M | $-35.34M |
| Inventory | $- | $-12.57M | $- | $2.86M | $17.07M |
| Accounts Payables | $-30.27M | $16.23M | $47.69M | $17.84M | $25.01M |
| Other Working Capital | $- | $648.00K | $12.12M | $-3.28M | $605.00K |
| Other Non Cash Items | $3.92M | $15.56M | $13.79M | $9.82M | $5.64M |
| Net Cash Provided by Operating Activities | $179.10M | $188.81M | $80.39M | $26.04M | $36.20M |
| Investments in Property Plant and Equipment | $-5.41M | $-3.64M | $-3.24M | $-2.13M | $-1.04M |
| Acquisitions Net | $-5.30M | $- | $40.62M | $-10.89M | $38.99M |
| Purchases of Investments | $-170.34M | $-429.69M | $-163.33M | $-111.48M | $-103.96M |
| Sales Maturities of Investments | $376.84M | $232.81M | $122.71M | $122.37M | $64.97M |
| Other Investing Activities | $- | $- | $-40.62M | $10.89M | $-38.99M |
| Net Cash Used for Investing Activities | $195.79M | $-200.53M | $-43.87M | $8.77M | $-40.03M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $6.13M | $3.07M | $4.27M | $2.68M |
| Common Stock Repurchased | $-300.28M | $-17.20M | $-12.09M | $-17.97M | $-8.93M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-9.60M | $-11.07M | $-7.86M | $-13.70M | $-6.25M |
| Net Cash Used Provided by Financing Activities | $-309.88M | $-11.07M | $-7.86M | $-13.70M | $-6.25M |
| Effect of Forex Changes on Cash | $1.00K | $1.00K | $- | $- | $- |
| Net Change in Cash | $65.02M | $-22.78M | $28.66M | $21.11M | $-10.08M |
| Cash at End of Period | $162.31M | $97.30M | $120.08M | $91.41M | $70.31M |
| Cash at Beginning of Period | $97.30M | $120.08M | $91.41M | $70.31M | $80.38M |
| Operating Cash Flow | $179.10M | $188.81M | $80.39M | $26.04M | $36.20M |
| Capital Expenditure | $-5.41M | $-3.64M | $-3.24M | $-2.13M | $-1.04M |
| Free Cash Flow | $173.70M | $185.17M | $77.15M | $23.91M | $35.17M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $10.53M | $10.42M | $16.48M | $16.90M | $13.47M | $15.90M | $14.99M | $17.68M | $3.41M | $13.21M | $8.77M | $4.97M | $15.08M | $16.80M | $18.73M | $15.17M | $38.86M | $5.36M | $-1.81M | $4.06M |
| Depreciation and Amortization | $868.00K | $837.00K | $754.00K | $716.00K | $634.00K | $579.00K | $527.00K | $541.00K | $446.00K | $405.00K | $386.00K | $364.00K | $316.00K | $267.00K | $296.00K | $422.00K | $464.00K | $462.00K | $460.00K | $520.00K |
| Deferred Income Tax | $-20.81M | $4.83M | $2.65M | $2.88M | $-2.12M | $5.04M | $2.17M | $-1.35M | $127.00K | $-1.67M | $85.00K | $-5.16M | $-15.45M | $-7.68M | $-6.81M | $-3.37M | $-38.09M | $1.24M | $1.21M | $116.00K |
| Stock Based Compensation | $30.86M | $33.18M | $33.04M | $31.05M | $28.80M | $31.25M | $31.75M | $30.81M | $29.30M | $23.30M | $23.65M | $24.50M | $15.01M | $7.15M | $6.52M | $5.03M | $4.16M | $3.07M | $3.54M | $2.05M |
| Change in Working Capital | $23.99M | $24.57M | $2.46M | $-27.03M | $-6.26M | $-2.55M | $22.85M | $-31.46M | $14.13M | $-17.93M | $-17.46M | $-38.22M | $-8.70M | $5.22M | $-28.51M | $-19.26M | $-731.00K | $5.18M | $-1.22M | $4.12M |
| Accounts Receivables | $41.70M | $9.92M | $-1.38M | $-60.12M | $22.02M | $-9.07M | $43.74M | $-78.42M | $13.86M | $-31.76M | $-35.56M | $-65.84M | $-1.94M | $3.17M | $-26.39M | $-43.52M | $-384.00K | $-14.55M | $-346.00K | $-20.05M |
| Inventory | $- | $- | $- | $- | $1.07M | $4.58M | $-5.66M | $- | $- | $- | $- | $- | $-10.64M | $2.48M | $569.00K | $10.46M | $-1.56M | $8.50M | $- | $- |
| Accounts Payables | $-35.34M | $-21.32M | $21.61M | $4.79M | $-6.65M | $2.03M | $-15.59M | $36.45M | $4.98M | $11.63M | $7.90M | $23.17M | $6.17M | $583.00K | $-2.71M | $13.80M | $1.29M | $10.89M | $-7.53M | $20.36M |
| Other Working Capital | $17.63M | $35.98M | $-17.77M | $28.30M | $-21.63M | $-89.00K | $360.00K | $10.52M | $-4.71M | $158.00K | $10.19M | $4.45M | $-2.29M | $-1.01M | $13.00K | $7.00K | $-72.00K | $350.00K | $6.65M | $3.82M |
| Other Non Cash Items | $6.72M | $-29.33M | $1.32M | $89.03M | $3.13M | $3.97M | $3.72M | $4.74M | $4.11M | $13.55M | $3.82M | $2.28M | $2.56M | $2.42M | $2.31M | $2.54M | $1.87M | $19.00K | $18.00K | $1.28M |
| Net Cash Provided by Operating Activities | $52.16M | $44.52M | $56.69M | $25.73M | $37.66M | $54.18M | $76.01M | $20.96M | $51.52M | $20.89M | $19.25M | $-11.26M | $8.81M | $24.16M | $-7.47M | $532.00K | $6.54M | $15.33M | $2.20M | $12.14M |
| Investments in Property Plant and Equipment | $-1.90M | $-1.79M | $-866.00K | $-850.00K | $-681.00K | $-953.00K | $-759.00K | $-1.25M | $-721.00K | $-1.24M | $-490.00K | $-790.00K | $-612.00K | $-718.00K | $-430.00K | $-369.00K | $-97.00K | $-149.00K | $-98.00K | $-693.00K |
| Acquisitions Net | $- | $- | $-5.30M | $- | $92.73M | $63.36M | $58.16M | $-502.00K | $452.00K | $- | $769.00K | $- | $- | $- | $- | $- | $-27.98M | $- | $- | $- |
| Purchases of Investments | $- | $-11.70M | $-47.83M | $-110.81M | $-166.73M | $-142.36M | $-97.16M | $-23.43M | $-38.18M | $-30.55M | $-34.74M | $-59.87M | $-21.00M | $-7.00M | $-21.34M | $-62.15M | $-38.99M | $-23.00M | $- | $- |
| Sales Maturities of Investments | $76.89M | $28.86M | $140.10M | $131.00M | $74.00M | $79.00M | $39.00M | $40.81M | $37.73M | $29.91M | $33.98M | $21.10M | $15.30M | $30.09M | $52.99M | $24.00M | $50.97M | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $20.19M | $-92.73M | $-63.36M | $-58.16M | $502.00K | $-452.00K | $-636.00K | $-769.00K | $-38.77M | $-5.70M | $23.09M | $31.65M | $-38.15M | $27.98M | $14.00M | $-41.98M | $- |
| Net Cash Used for Investing Activities | $74.99M | $15.36M | $86.10M | $19.34M | $-93.41M | $-64.31M | $-58.92M | $16.13M | $-1.17M | $-1.88M | $-1.26M | $-39.56M | $-6.31M | $22.37M | $31.22M | $-38.52M | $11.89M | $-9.15M | $-42.08M | $-693.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $1.67M | $716.00K | $1.77M | $1.68M | $3.07M | $- | $569.00K | $1.22M | $1.55M | $755.00K | $944.00K | $1.03M | $427.00K | $- | $- | $- |
| Common Stock Repurchased | $-55.10M | $-61.45M | $-159.96M | $-23.76M | $-6.70M | $-3.08M | $-3.61M | $-3.81M | $-4.13M | $-2.32M | $-2.65M | $-2.99M | $- | $-3.81M | $-5.77M | $-3.52M | $- | $- | $-4.10M | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-1.23M | $-1.90M | $-2.83M | $-3.65M | $-5.03M | $-2.36M | $-1.84M | $-1.85M | $-2.79M | $-1.23M | $-2.08M | $-1.77M | $-3.31M | $-3.06M | $-4.82M | $-2.50M | $-2.51M | $715.00K | $-2.36M | $-194.00K |
| Net Cash Used Provided by Financing Activities | $-56.33M | $-63.35M | $-162.79M | $-27.41M | $-5.03M | $-2.36M | $-1.84M | $-1.85M | $-2.79M | $-1.23M | $-2.08M | $-1.77M | $-3.31M | $-3.06M | $-4.82M | $-2.50M | $-2.08M | $-1.61M | $-2.36M | $-194.00K |
| Effect of Forex Changes on Cash | $7.00K | $-4.00K | $- | $-2.00K | $1.00K | $65.26M | $34.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00K | $-1.00K |
| Net Change in Cash | $70.83M | $-3.48M | $-20.00M | $17.66M | $-60.78M | $-12.49M | $15.25M | $35.24M | $47.56M | $17.79M | $15.91M | $-52.59M | $-811.00K | $43.48M | $18.93M | $-40.48M | $16.34M | $4.57M | $-42.24M | $11.25M |
| Cash at End of Period | $162.31M | $91.48M | $94.96M | $114.96M | $97.30M | $158.07M | $170.57M | $155.32M | $120.08M | $72.52M | $54.73M | $38.82M | $91.41M | $92.22M | $48.75M | $29.82M | $70.31M | $53.97M | $49.39M | $91.63M |
| Cash at Beginning of Period | $91.48M | $94.96M | $114.96M | $97.30M | $158.07M | $170.57M | $155.32M | $120.08M | $72.52M | $54.73M | $38.82M | $91.41M | $92.22M | $48.75M | $29.82M | $70.31M | $53.97M | $49.39M | $91.63M | $80.38M |
| Operating Cash Flow | $52.16M | $44.52M | $56.69M | $25.73M | $37.66M | $54.18M | $76.01M | $20.96M | $51.52M | $20.89M | $19.25M | $-11.26M | $8.81M | $24.16M | $-7.47M | $532.00K | $6.54M | $15.33M | $2.20M | $12.14M |
| Capital Expenditure | $-1.90M | $-1.79M | $-866.00K | $-850.00K | $-681.00K | $-953.00K | $-759.00K | $-1.25M | $-721.00K | $-1.24M | $-490.00K | $-790.00K | $-612.00K | $-718.00K | $-430.00K | $-369.00K | $-97.00K | $-149.00K | $-98.00K | $-693.00K |
| Free Cash Flow | $50.27M | $42.72M | $55.83M | $24.88M | $36.98M | $53.23M | $75.25M | $19.71M | $50.80M | $19.65M | $18.76M | $-12.05M | $8.20M | $23.45M | $-7.90M | $163.00K | $6.44M | $15.18M | $2.10M | $11.45M |
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
$22.96
Stock Price
$1.97B
Market Cap
680
Employees
New York, NY
Location
Revenue (FY 2024)
$1.17B
7.2% YoY
Net Income (FY 2024)
$54.34M
-12.4% YoY
EPS (FY 2024)
$0.57
-8.1% YoY
Free Cash Flow (FY 2024)
$173.70M
-6.2% YoY
Profitability
Gross Margin
21.7%
Net Margin
4.7%
ROE
12.9%
ROA
9.0%
Valuation
P/E Ratio
29.04
P/S Ratio
1.35
EV/EBITDA
21.27
Market Cap
$1.97B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$179.10M
-5.1% YoY
Free Cash Flow
$173.70M
-6.2% YoY
Balance Sheet Summary
Total Assets
$607.10M
-19.8% YoY
Total Debt
$19.27M
0.6% YoY
Shareholder Equity
$422.06M
-20.8% YoY
Dividend Overview
No Dividend Data
Progyny, Inc. doesn't currently pay dividends.
Progyny Dividends
Explore Progyny's dividend history, including dividend yield, payout ratio, and historical payments.
Progyny News
Read the latest news about Progyny, including recent articles, headlines, and updates.
Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building, will report its financial results for the quarterly period ended March 31, 2025, after the close of the market on Thursday, May 8, 2025.
Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer
The leadership additions support the company's continued ability to scale as it delivers the right care model for women's health and family building The leadership additions support the company's continued ability to scale as it delivers the right care model for women's health and family building
Progyny to Host Events Honoring Individuals, Families and Infertility Throughout National Infertility Awareness Week® and Canadian Fertility Awareness Week®
As awareness around the need for expanded access and coverage of fertility grows, Progyny lifts off the conversation and provides a platform for the millions of individuals facing family building challenges As awareness around the need for expanded access and coverage of fertility grows, Progyny lifts off the conversation and provides a platform for the millions of individuals facing family building challenges
The Broken Brown Egg and Progyny Announce the 2025 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family Building
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, and The Broken Brown Egg, a nonprofit supporting BIPOC individuals and couples experiencing infertility, today announced the launch of their 2025 Awareness, Hope, and Activism (AHA) Grant, marking the fourth consecutive year of this family building partnership.
Progyny Expands Maternal Health Support with Addition of Doula Services
Available to employers and health plans, the in-person and virtual doula care services can close more care gaps and improve health outcomes Available to employers and health plans, the in-person and virtual doula care services can close more care gaps and improve health outcomes
Progyny Expands Family Building Solutions with New Parent and Child Well-being Offering
The in-demand program provides high-touch, holistic support for working parents and caregivers, addressing return-to-work challenges, emotional health support, and benefit navigation The in-demand program provides high-touch, holistic support for working parents and caregivers, addressing return-to-work challenges, emotional health support, and benefit navigation
Progyny, Inc. to Participate in Upcoming Investor Conferences
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced it expects to participate in several upcoming investor conferences. Progyny executives will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on Monday, March 10, 2025, at 11:20 a.m. Eastern Time. The executives will then be participating in meetings at the Barclays 27th Annual Global Healthcare Conference in Miami, FL on Tuesday, March 11, 2025.
PGNY CEO on "Well-Positioned" Sales Year & Expanding Footprint
Pete Anevski, CEO of Progyny (PGNY), discusses his company's latest earnings and how it's poised for a "well-positioned" year. He notes general healthcare headwinds for the women's health company, though he expects Progyny to find new clients and retain current customers.
Progyny Tops EPS Forecast, Eyes Growth
Progyny (PGNY -1.68%), a pioneer in fertility benefits management, released its earnings for the fourth quarter on Feb. 27. The standout points were its impressive revenue and adjusted earnings per share (EPS) results, both of which surpassed analysts' consensus predictions.
Progyny, Inc. (PGNY) Q4 2024 Earnings Call Transcript
Progyny, Inc. (NASDAQ:PGNY ) Q4 2024 Earnings Conference Call February 27, 2025 4:45 PM ET Company Participants James Hart - Investor Relations Pete Anevski - Chief Executive Officer Mark Livingston - Chief Financial Officer Michael Sturmer - President Conference Call Participants Anne Samuel - JPMorgan Michael Cherny - Leerink Partners John Pinney - Canaccord Genuity Scott Schoenhaus - KeyBanc Jailendra Singh - Truist Securities Allen Lutz - Bank of America Sarah James - Cantor Constantine Davides - Citizens JMP Jenny Shen - BTIG Operator Good day, ladies and gentlemen. Welcome to the Progyny, Inc. Fourth Quarter Earnings Conference Call.
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2024 Results Report
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2024, after the close of the market on Thursday, February 27, 2025. The company will host a conference call at 4:45 p.m.
Kuehn Law Encourages Investors of Progyny, Inc. to Contact Law Firm
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Progyny, Inc. (NASDAQ: PGNY) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Progyny, Inc. Enhances Suite of Services with Acquisition of BenefitBump
Provides expecting parents with a concierge-level service model that delivers expert guidance, navigation and support for parental leave planning Provides expecting parents with a concierge-level service model that delivers expert guidance, navigation and support for parental leave planning
Progyny Appoints Healthcare Veteran Debra Morris to Board of Directors
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building and women's health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025.
Cigna Healthcare Expands Access to Fertility and Family-Building Benefits and Services
BLOOMFIELD, Conn. , Jan. 13, 2025 /PRNewswire/ -- Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), today announced a new offering in collaboration with Progyny, Inc (Nasdaq: PGNY) that makes best-in-class fertility and family-building services accessible and equitable for more employers.
The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
Progyny shares have plummeted nearly 80% from 2021's peak, but management optimism and insider buying in December signal a potential turnaround during 2025. PGNY's valuation is deeply discounted, with strong fundamentals: $235M in cash, no debt, and 9.64% in trailing free cash flow yield. The stock's rare accumulation/momentum pattern since September and potential short squeeze kicker make it an attractive Buy.
PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders
SAN DIEGO , Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.
Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.
Progyny: Rating Downgrade On Uncertain Growth Outlook
I recommend downgrading Progyny from buy to hold due to a loss of confidence in its growth outlook and increased uncertainty. PGNY's Q3 2024 results were disappointing, with revenue and margins falling short of expectations, leading to lowered FY24 guidance. Declines in ART cycles and a weaker 2024 sales season raise concerns about underlying demand, despite potential upsides from upselling adjacent solutions.
Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
I initially rated Progyny a "Buy" in late 2022, but 2024 has been disastrous, with a 60% stock drop and loss of Amazon as a client. Q3 2024 financials show minimal revenue growth, declining margins, and lower earnings per share, despite a strong balance sheet. Given management's struggles and increased competition, I no longer believe Progyny has a competitive advantage and have sold my shares.
Progyny, Inc. to Present at Jefferies London Healthcare Conference
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT (3:00 a.m. EST).
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PGNY.